Relmada Therapeutics Operating Income

Relmada Therapeutics (RLMD) currently reports a operating income of $-65M as of June 2026. That compares with $-71M in the prior-year period — up 7.6% year over year. Use the charts on this page to explore Relmada Therapeutics's operating income history and peer comparisons.

Relmada Therapeutics's operating income increased from $-71M to $-65M — a 7.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Relmada Therapeutics reported $-65M in operating income as of June 2026. That compares with $-71M in the prior-year period — up 7.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-65M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Relmada Therapeutics, and consider following RLMD for alerts when major investors trade the stock.

Relmada Therapeutics is classified in the Consumer Discretionary sector. On operating income, it currently shows $-65M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Consumer Discretionary are usually more informative than comparing RLMD with unrelated industries.